Vertex Pharmaceuticals has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX, its newly approved non-opioid medicine for moderate-to-severe acute pain. After rupturing his Achilles tendon during the 2025 playoffs, Tatum turned to JOURNAVX as an alternative to opioids, citing its effectiveness in managing his post-surgical pain without the side effects he experienced from traditional treatments. The FDA approved JOURNAVX in January 2025, making it the first new class of acute pain medicine in over two decades. By sharing his recovery story, Tatum hopes to encourage others to explore non-opioid options, while Vertex underscores its commitment to offering safer alternatives in pain management.